REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
Volume 0.70M
Average 1.24M
RGNX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
REGENXBIO Inc.NASDAQ: RGNX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $8.62M rose 0.9% year over year, ahead of the -7.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at -5.4% a year.
Context
- Stock-based compensation amounted to 20.3% of revenue in FY2025, down 25.9 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.9% holds above the trailing-twelve-month pace of -7.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 34.56M USD
- Year-over-year change
- -10.1%
- 4-year CAGR
- -2.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.56M | -10.1% |
| FY2024 | 2024-12-31 | 38.46M | -4.5% |
| FY2023 | 2023-12-31 | 40.27M | -1.3% |
| FY2022 | 2022-12-31 | 40.79M | +5.1% |
| FY2021 | 2021-12-31 | 38.81M | — |
Stock-Based Compensation vs competitors
How RGNX compares with its peers on the latest reported figures
- RGNX's LTM Mar 2026 stock-based compensation of $34.64M is the 3rd largest of the 10 companies compared; the peer median is $18.36M.
- Its year-over-year change of -7.4% is the 6th highest of 10, against a peer median of -5.7%.
- Stock-based compensation amounts to 39.4% of revenue for RGNX, versus a peer median of 48.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.93M | +107.3% | -8.3% | 60.1% | |
| LTM Mar 2026 | $35.22M | -20.0% | +6.1% | — | |
| LTM Mar 2026 | $34.64M | -7.4% | -5.4% | 39.4% | |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| LTM Mar 2026 | $18.36M | -5.7% | -19.7% | 101.5% | |
| LTM Mar 2026 | $13.6M | -8.6% | +16.5% | 37.3% | |
| LTM Jun 2026 | $13.14M | +42.2% | +2.1% | 15.3% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.19M | -19.1% | +89.6% | — |
| LTM Mar 2026 | $9.22M | +22.1% | -9.9% | 206.5% | |
| Peer median (excluding RGNX) | $18.36M | -5.7% | +6.1% | 48.7% | |
Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 127.84M | (280.32M) | (263.49M) | (227.1M) | (193.88M) |
| Depreciation & Amortization | 9.56M | 12.91M | 17.32M | 16.22M | 15.62M |
| Deferred Income Tax | (1.92M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 38.81M | 40.79M | 40.27M | 38.46M | 34.56M |
| Change in Working Capital | 40.22M | 13.98M | (10.89M) | 5.53M | 11.78M |
| Accounts Receivables | 14.12M | 4.82M | 3.94M | 9.71M | (7.66M) |
| Inventory | 29.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.3M) | 18.79M | (2.79M) | (292K) | (2.28M) |
| Other Working Capital | (899K) | (9.64M) | (12.03M) | (3.88M) | 21.73M |
| Other Non-Cash Items | 4.36M | 5.16M | (1.61M) | (6.23M) | 7.96M |
| Operating Cash Flow | 218.88M | (207.49M) | (218.41M) | (173.13M) | (123.96M) |
| Capital Expenditures | (84.18M) | (30.72M) | (9.96M) | (2.44M) | (2.41M) |
| Acquisitions (Net) | (4.99M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (498.14M) | (184.88M) | (86.56M) | (190.14M) | (332.63M) |
| Sales of Investments | 175.68M | 203.67M | 287.47M | 290.24M | 319.11M |
| Other Investing Activities | 4.99M | 0 | 0 | 5.78M | 62K |
| Investing Cash Flow | (406.64M) | (11.93M) | 190.94M | 103.45M | (15.87M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 218.21M | 1.74M | 6.7M | 131.07M | 1.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 1.19M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22.96M) | (30.58M) | (41.67M) | (39.58M) | 115.76M |
| Financing Cash Flow | 195.25M | (28.84M) | (34.97M) | 92.68M | 116.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 7.48M | (248.26M) | (62.43M) | 23M | (23.06M) |
| Free Cash Flow | 134.7M | (238.21M) | (228.37M) | (175.56M) | (126.38M) |
REGENXBIO Inc.
NASDAQ:RGNX
Intrinsic Alpha fair value
Locked
Current Price
$7.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.